Diabetes, Pre-Diabetes
Conditions
Keywords
Pre-Diabetes, cinnamon
Brief summary
The purpose of this study is to assess whether water-soluble cinnamon extract plus aggressive lifestyle intervention is effective in lowering blood glucose in pre-diabetic patients when compared to aggressive lifestyle therapy plus placebo.
Detailed description
We are studying whether water-soluble cinnamon extract (Cinnulin PF) plus standard of care aggressive lifestyle therapy is effective in lowering blood glucose when compared to placebo plus standard of care aggressive life style therapy. Eligible subjects will be recruited from any form and any stage of standard lifestyle intervention for pre-diabetes at an individual base. Standard lifestyle intervention for pre-diabetes could include Group Lifestyle Balance (GLB), nutrition classes, Better Body/Better Life, or anything an investigator certifies as standard practice at that base. Subjects will take either 1 gram (2-500 milligram (mg) capsules) of water-soluble cinnamon extract (Cinnulin PF) or 2 placebo pills (gelatin capsule filled with wheat bran) once a day for 1 year plus 1 additional year of follow-up. This is a randomized, double-blind, multicenter, placebo-controlled study which will enroll subjects at the Mike O'Callaghan Federal Medical Center (MOFMC), Wilford Hall Ambulatory Surgical Center (WHASC), David Grant Medical Center (DGMC), Eglin Air Force Base (Eglin), and Offutt Air Force Base (Offutt). All subjects will be MOFMC, WHASC, DGMC, Eglin, and Offutt DoD beneficiaries. Informed Consent and HIPAA Authorization will be obtained. After randomization, subjects will receive either 1 gram (2-500 mg capsules) of water-soluble cinnamon extract or placebo from the pharmacy--thus investigators and subjects will be blinded as to if they are taking Cinnulin PF or 2 placebo pills. Subjects will be permitted to have usual medical care for other co-morbid, preventive, and acute conditions. Analysis will be performed using intention-to-treat principles for missing data (the carry-forward method to impute missing data will be used). Subjects will bring in any remaining water-soluble cinnamon extract or placebo to determine adherence rates to the study protocol.
Interventions
DRUGwater-soluble cinnamon extract (Cinnulin PF)
Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
Sponsors
Mike O'Callaghan Military Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY. Inclusion: Patients will be MOFMC, WHASC, DGMC, Eglin, and Offutt DoD beneficiaries, ages 18-65 years. Diagnosis of pre-diabetes (defined as a fasting plasma glucose (FPG) 100-125mg/dl, Hemoglobin A1c 5.7-6.4%, or a 2-hour oral glucose tolerance test (OGTT) 140-199). Exclusion: Patients who are less than 18 yrs of age or greater than 65 years of age. Patients who are known to have or develop during the study any of the following upon review of their medical record: * Diabetes Mellitus (defined as fasting plasma glucose (FPG) greater than 126mg/dl, hemoglobin A1C greater than 6.5%, or a 2-hour oral glucose tolerance test (OGTT) greater than 200mg/dl) * Stage 3 kidney disease or worse * Renal insufficiency defined as a glomerular filtration rate (gfr) of less than 60ml * Celiac disease * Insulinoma * Cushing's disease * Hyperthyroidism * Acromegaly * Pheochromocytoma * Addison's disease * Galactosemia * Glycogen storage disease * Hereditary fructose intolerance Patients taking any of the following: * Cinnamon as a dietary supplement * Daily oral steroids * Warfarin * Hypoglycemic medication * Weight loss medication * Digoxin, lithium, phenytoin, & theophylline (due to their narrow therapeutic indices) Patients who are pregnant or breast feeding Patients with a known allergy to cinnamon Patients with a known allergy to wheat
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Water-soluble Cinnamon | 1 year | Does water-soluble cinnamon extract delay the onset of diabetes or extend the time to diagnosis of diabetes in pre-diabetic patients who are already undergoing aggressive lifestyle therapy? |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cinnulin PF Will take (by mouth) 2 gelatin capsules that contains 1 gram (2-500 mg capsules) water-soluble cinnamon extract (Cinnulin PF) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
water-soluble cinnamon extract (Cinnulin PF): Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy | 116 |
| Placebo Will take (by mouth) 2 placebo capsules (gelatin capsule filled with wheat bran) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
water-soluble cinnamon extract (Cinnulin PF): Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy | 113 |
| Total | 229 |
Baseline characteristics
| Characteristic | Cinnulin PF | Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 116 Participants | 113 Participants | 229 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 10 Participants | 9 Participants | 19 Participants |
| Race (NIH/OMB) Black or African American | 38 Participants | 20 Participants | 58 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 6 Participants | 7 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 13 Participants | 7 Participants | 20 Participants |
| Race (NIH/OMB) White | 53 Participants | 69 Participants | 122 Participants |
| Sex: Female, Male Female | 64 Participants | 61 Participants | 125 Participants |
| Sex: Female, Male Male | 52 Participants | 52 Participants | 104 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 116 | 0 / 113 |
| other Total, other adverse events | 41 / 116 | 30 / 113 |
| serious Total, serious adverse events | 0 / 116 | 0 / 113 |
Outcome results
Primary
Water-soluble Cinnamon
Does water-soluble cinnamon extract delay the onset of diabetes or extend the time to diagnosis of diabetes in pre-diabetic patients who are already undergoing aggressive lifestyle therapy?
Time frame: 1 year
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cinnulin PF | Water-soluble Cinnamon | diabetes conversion: yes | 15 Participants |
| Cinnulin PF | Water-soluble Cinnamon | diabetes conversion: no | 32 Participants |
| Placebo | Water-soluble Cinnamon | diabetes conversion: yes | 11 Participants |
| Placebo | Water-soluble Cinnamon | diabetes conversion: no | 32 Participants |